Compugen Ltd
Veridion Score
Composite trend over time
Why is CGEN moving today?
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CGEN.
CGEN insider activity
Compugen Ltd
2 insiders bought in the last 90 days
Net selling: -$78K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 2026-04-24 | Levine Zurit | Insider | sell | $3.20 | 2,000 | 29,375 | $6K | SEC Form 4 |
| 2026-04-27 | 2026-04-24 | Levine Zurit | Insider | buy | $1.15 | 2,000 | 31,375 | $2K | SEC Form 4 |
| 2026-04-27 | 2026-04-24 | Ophir Eran | Insider | sell | $3.20 | 5,000 | 11,375 | $16K | SEC Form 4 |
| 2026-04-27 | 2026-04-24 | Ophir Eran | Insider | buy | $0.83 | 5,000 | 16,375 | $4K | SEC Form 4 |
| 2026-04-15 | 2026-04-14 | Ophir Eran | Insider | sell | $2.90 | 5,000 | 11,375 | $15K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 21 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCGEN contract awards, year to date.
Public federal awards linked to this ticker.
CGEN lobbying filings, year to date.
Registered lobbying filings matched to Compugen Ltd.